Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
09:05am, Tuesday, 16'th Dec 2025
A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss g
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
08:55am, Tuesday, 16'th Dec 2025
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and
Where Will Eli Lilly Be in 10 Years?
05:15am, Tuesday, 16'th Dec 2025
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). The company overtook early GLP-1 leader Novo Nordisk.
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
09:51am, Thursday, 11'th Dec 2025
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)
08:30am, Tuesday, 09'th Dec 2025
Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top or
Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump
08:21am, Monday, 08'th Dec 2025
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets.
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
Hims & Hers: The Market's Panic Is Irrational
04:39am, Sunday, 07'th Dec 2025
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
02:56pm, Thursday, 04'th Dec 2025
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglut
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
10:15pm, Wednesday, 03'rd Dec 2025
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
08:06pm, Wednesday, 03'rd Dec 2025
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
03:42pm, Tuesday, 02'nd Dec 2025
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday,
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
